Novartis Loses Bid To End Wyeth ReFacto Patent Suit

Law360, New York (May 7, 2009, 12:00 AM EDT) -- Novartis AG has failed to have claims against it dismissed or transferred in an ongoing battle with Wyeth subsidiary Genetics Institute over who legally owns the formula for ReFacto, a drug used to treat hemophilia.

U.S. District Judge Sue Robinson of the U.S. District Court for the District of Delaware on Thursday denied Novartis' motions, ruling that Novartis had failed to show that GI did not hold the rights to the patent it asserted.

Novartis had mounted an affirmative defense and counterclaim against GI, contending that...
To view the full article, register now.